Robert Harrington to Cholesterol
This is a "connection" page, showing publications Robert Harrington has written about Cholesterol.
Connection Strength
0.267
-
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.
Score: 0.148
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
Score: 0.045
-
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 11 21; 41(44):4245-4255.
Score: 0.040
-
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol. 2008 Nov 01; 102(9):1119-24.
Score: 0.017
-
Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007 Nov 15; 100(10):1538-42.
Score: 0.016